A systematic review of second-line controller combination therapy options for the management of asthma
- 9 Downloads
First-line controller combination therapy for the management of asthma is a low-dose inhaled corticosteroid (LD-ICS) + a long-acting β-agonist (LABA), and second-line options are a LD-ICS + a leukotriene receptor antagonist (LTRA), LD-ICS + sustained-release theophylline (SR-T), and a medium-/high-dose ICS (HD-ICS).
The purpose of this review is to assess the various second-line combination therapy options for the management of asthma.
We systematically reviewed randomized controlled trials (RCTs) in adult patients with asthma, extracting and synthesizing data from eligible articles on study design, duration, randomization, blinding, withdrawal, run-in period, type of analysis, and names and doses of drugs. The primary outcome measure was change in percentage predicted forced expiratory volume in 1 second (% FEV1), and the secondary outcome was frequency of asthma exacerbations.
Nine RCTs (three blinded and six open-label trials) were selected for the review. One study investigated LD-ICS + LTRA compared with HD-ICS, two studies investigated LD-ICS + SR-T compared with HD-ICS, and five studies investigated LD-ICS + LTRA compared with LD-ICS + SR-T. Only one of the nine RCTs compared all treatment options as mentioned in Global Initiative for Asthma (GINA) guidelines. Seven RCTs examined the primary outcome (change in % FEV1). No significant difference was observed (four RCTs; % FEV1) between LD-ICS + LTRA and LD-ICS + SR-T, but one RCT reported better clinical improvement with LD-ICS + LTRA than with LD-ICS + SR-T (% FEV1). Likewise, similar clinical effects (two RCTs) were observed between LD-ICS + SR-T and HD-ICS, one based on % FEV1 and the other based on exacerbation improvement. One RCT concluded that LD-ICS + LTRA was an effective and well-tolerated alternative to HD-ICS (exacerbation improvement). LD-ICS + LTRA resulted in greater clinical improvement when comparing all second-line treatment options in one RCT (% FEV1 and exacerbation improvement). All nine studies had a high risk of bias according to a modified Cochrane risk-of-bias tool for quality assessment of RCTs.
Existing RCTs provide low-quality evidence of the superiority of second-line controller options for asthma management. This systematic review recommends that clinically relevant, stringently designed RCTs with appropriate sample sizes and durations are conducted to identify the best second-line controller option.
Compliance with ethical standards
Conflict of interest
MGR, SPA, RA, AA, JGB have no conflicts of interest that are directly relevant to the content of this article.
No sources of funding were used to conduct this study or prepare this manuscript.
- 3.Rajanandh MG, Nageswari AD, Irshad PP, et al. Dose-reduction of inhaled corticosteroids with the addition of leukotriene antagonist is clinical significance in asthma patients? A randomized clinical trial. World Appl Sci J. 2013;24:276–81.Google Scholar
- 4.Ilango K, Rajanaandh MG, Nageswari AD. Roflumilast, an upcoming drug for curing asthma and COPD. Int J Pharm Res Tech. 2013;5:130–5.Google Scholar
- 11.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Update 2012. http://www.ginasthma.org/documents/4. Accessed 16 Sept 2011.
- 14.Rajanandh MG, Nageswari AD, Ilango K. Development and validation of knowledge, attitude, practice questionnaire for asthma and assessment of impact of patient education on asthma patients. Int J Pharm Pharm Sci. 2014;6:309–11.Google Scholar
- 20.Price DB, Hemandez D, Magyar P, et al. Clinical outcomes with montelukast as a partner agent to corticosteroid therapy (COMPACT) international study group: randomized controlled trial of montelukast plus inhaled budesonide versus double dose of inhaled corticosteroids in adult patients with asthma. Thorax. 2003;58:211–6.CrossRefPubMedPubMedCentralGoogle Scholar